Inibizione del TNFα in pazienti con anticorpi anti-Ro/SSA e artrite reumatoide: Analisi clinica e sierologica

Translated title of the contribution: TNF α inhibition in anti-Ro/SSA positive patients with rheumatoid arthritis: Clinical and immunological effects

Ilaria Cavazzana, F. Bobbio-Pallavicini, C. Bazzani, E. Bravi, S. Zingarelli, A. Ceribelli, R. Caporali, R. Cattaneo, F. Franceschini, C. Montecucco

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: to analyse efficacy and safety of anti-TNF α treatment in 17 patients with rheumatoid arthritis (AR) and anti-Ro antibodies, in order to detect difference in clinical and immunological response. Methods: 322 patients, affected by RA and treated with anti-TNF α drugs, were considered, searching every 6-12 months ANA, anti-dsDNA and anti-ENA antibodies. Seventeen were anti-Ro positive and 305 anti-Ro negative before starting treatment. Results: anti-Ro positive subjects showed active arthritis at baseline (mean DAS: 5), with frequent extra-articular features, such as ocular and oral sicca symptoms. They showed rapid and stable improvement during the treatment, without significant difference compared to anti-Ro negative group. A good clinical Eular response was shown in 46% of anti-Ro negative subjects, steady stable during time. On the contrary, fewer anti-Ro positive patients seem to be "good" responders. RA remission (DAS th month, while they slightly increased in first 12 months in anti-Ro negative ones, then decreased to baseline value. No differences were shown about the frequency and reasons of anti-TNF α withdrawal, except for cutaneous lupus-like disease, more detected in anti-Ro positive group. Conclusions: anti-TNF α drugs are effective in anti-Ro positive RA as well as other RA patients. Anti-DNA positivity and lupus-like disease were more frequently observed in anti-Ro positive group.

Original languageItalian
Pages (from-to)275-282
Number of pages8
JournalReumatismo
Volume58
Issue number4
Publication statusPublished - 2006

Fingerprint

amsonic acid
Rheumatoid Arthritis
Pharmaceutical Preparations
Arthritis
Anti-Idiotypic Antibodies
Therapeutics
Joints
Safety
Skin
DNA

ASJC Scopus subject areas

  • Rheumatology

Cite this

Inibizione del TNFα in pazienti con anticorpi anti-Ro/SSA e artrite reumatoide : Analisi clinica e sierologica. / Cavazzana, Ilaria; Bobbio-Pallavicini, F.; Bazzani, C.; Bravi, E.; Zingarelli, S.; Ceribelli, A.; Caporali, R.; Cattaneo, R.; Franceschini, F.; Montecucco, C.

In: Reumatismo, Vol. 58, No. 4, 2006, p. 275-282.

Research output: Contribution to journalArticle

Cavazzana, Ilaria ; Bobbio-Pallavicini, F. ; Bazzani, C. ; Bravi, E. ; Zingarelli, S. ; Ceribelli, A. ; Caporali, R. ; Cattaneo, R. ; Franceschini, F. ; Montecucco, C. / Inibizione del TNFα in pazienti con anticorpi anti-Ro/SSA e artrite reumatoide : Analisi clinica e sierologica. In: Reumatismo. 2006 ; Vol. 58, No. 4. pp. 275-282.
@article{da10409fd4b4474bb137e6100842107b,
title = "Inibizione del TNFα in pazienti con anticorpi anti-Ro/SSA e artrite reumatoide: Analisi clinica e sierologica",
abstract = "Objective: to analyse efficacy and safety of anti-TNF α treatment in 17 patients with rheumatoid arthritis (AR) and anti-Ro antibodies, in order to detect difference in clinical and immunological response. Methods: 322 patients, affected by RA and treated with anti-TNF α drugs, were considered, searching every 6-12 months ANA, anti-dsDNA and anti-ENA antibodies. Seventeen were anti-Ro positive and 305 anti-Ro negative before starting treatment. Results: anti-Ro positive subjects showed active arthritis at baseline (mean DAS: 5), with frequent extra-articular features, such as ocular and oral sicca symptoms. They showed rapid and stable improvement during the treatment, without significant difference compared to anti-Ro negative group. A good clinical Eular response was shown in 46{\%} of anti-Ro negative subjects, steady stable during time. On the contrary, fewer anti-Ro positive patients seem to be {"}good{"} responders. RA remission (DAS th month, while they slightly increased in first 12 months in anti-Ro negative ones, then decreased to baseline value. No differences were shown about the frequency and reasons of anti-TNF α withdrawal, except for cutaneous lupus-like disease, more detected in anti-Ro positive group. Conclusions: anti-TNF α drugs are effective in anti-Ro positive RA as well as other RA patients. Anti-DNA positivity and lupus-like disease were more frequently observed in anti-Ro positive group.",
keywords = "Anti-Ro/SSA, Anti-TNFα, Rheumatoid arthritis",
author = "Ilaria Cavazzana and F. Bobbio-Pallavicini and C. Bazzani and E. Bravi and S. Zingarelli and A. Ceribelli and R. Caporali and R. Cattaneo and F. Franceschini and C. Montecucco",
year = "2006",
language = "Italian",
volume = "58",
pages = "275--282",
journal = "Reumatismo",
issn = "0048-7449",
publisher = "PAGEPRESS PUBL",
number = "4",

}

TY - JOUR

T1 - Inibizione del TNFα in pazienti con anticorpi anti-Ro/SSA e artrite reumatoide

T2 - Analisi clinica e sierologica

AU - Cavazzana, Ilaria

AU - Bobbio-Pallavicini, F.

AU - Bazzani, C.

AU - Bravi, E.

AU - Zingarelli, S.

AU - Ceribelli, A.

AU - Caporali, R.

AU - Cattaneo, R.

AU - Franceschini, F.

AU - Montecucco, C.

PY - 2006

Y1 - 2006

N2 - Objective: to analyse efficacy and safety of anti-TNF α treatment in 17 patients with rheumatoid arthritis (AR) and anti-Ro antibodies, in order to detect difference in clinical and immunological response. Methods: 322 patients, affected by RA and treated with anti-TNF α drugs, were considered, searching every 6-12 months ANA, anti-dsDNA and anti-ENA antibodies. Seventeen were anti-Ro positive and 305 anti-Ro negative before starting treatment. Results: anti-Ro positive subjects showed active arthritis at baseline (mean DAS: 5), with frequent extra-articular features, such as ocular and oral sicca symptoms. They showed rapid and stable improvement during the treatment, without significant difference compared to anti-Ro negative group. A good clinical Eular response was shown in 46% of anti-Ro negative subjects, steady stable during time. On the contrary, fewer anti-Ro positive patients seem to be "good" responders. RA remission (DAS th month, while they slightly increased in first 12 months in anti-Ro negative ones, then decreased to baseline value. No differences were shown about the frequency and reasons of anti-TNF α withdrawal, except for cutaneous lupus-like disease, more detected in anti-Ro positive group. Conclusions: anti-TNF α drugs are effective in anti-Ro positive RA as well as other RA patients. Anti-DNA positivity and lupus-like disease were more frequently observed in anti-Ro positive group.

AB - Objective: to analyse efficacy and safety of anti-TNF α treatment in 17 patients with rheumatoid arthritis (AR) and anti-Ro antibodies, in order to detect difference in clinical and immunological response. Methods: 322 patients, affected by RA and treated with anti-TNF α drugs, were considered, searching every 6-12 months ANA, anti-dsDNA and anti-ENA antibodies. Seventeen were anti-Ro positive and 305 anti-Ro negative before starting treatment. Results: anti-Ro positive subjects showed active arthritis at baseline (mean DAS: 5), with frequent extra-articular features, such as ocular and oral sicca symptoms. They showed rapid and stable improvement during the treatment, without significant difference compared to anti-Ro negative group. A good clinical Eular response was shown in 46% of anti-Ro negative subjects, steady stable during time. On the contrary, fewer anti-Ro positive patients seem to be "good" responders. RA remission (DAS th month, while they slightly increased in first 12 months in anti-Ro negative ones, then decreased to baseline value. No differences were shown about the frequency and reasons of anti-TNF α withdrawal, except for cutaneous lupus-like disease, more detected in anti-Ro positive group. Conclusions: anti-TNF α drugs are effective in anti-Ro positive RA as well as other RA patients. Anti-DNA positivity and lupus-like disease were more frequently observed in anti-Ro positive group.

KW - Anti-Ro/SSA

KW - Anti-TNFα

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=34247160832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247160832&partnerID=8YFLogxK

M3 - Articolo

C2 - 17216016

AN - SCOPUS:34247160832

VL - 58

SP - 275

EP - 282

JO - Reumatismo

JF - Reumatismo

SN - 0048-7449

IS - 4

ER -